Clinical Trial

Kaltenborn Versus Active Release on Temporomandibular Joint Dysfunction

Completed
View on ClinicalTrials.gov →
Summary
Temporomandibular disorder (TMD) is a term describing musculoskeletal conditions of the face, jaw and temporal regions. TMD is frequently associated with pain and/or dysfunction such as impaired jaw function, pain in the temporomandibular joint (TMJ), muscles and/or related structures, and associated headaches. The etiology of TMD is multifactorial and complex. It is known that one cause of TMD symptom development is treatment for head and neck cancer (HNC). The main treatment modalities for HNC include radiotherapy (RT) with or without chemotherapy and surgical intervention, as either a single therapy or a combination therapy. In the head and neck region, the anatomical structures are necessary for essential functions such as speech, swallowing, breathing, smell, and taste. The treatment of head and neck tumors may frequently impair some of these functions, which may result in pain, oral dysfunction, and impaired health-related quality of life.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-25; most recent amendment 2026-02-11.
Status change: Recruiting → Completed 2026-02-11
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07151469
Lead Sponsor MTI University
Conditions Head and Neck Cancer
Enrollment 115 participants
Start Date 2025-10-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-02-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-12